These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 15121313)

  • 61. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
    Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical manifestations of treatment-naive patients with acquired immunodeficiency syndrome and responses to highly active antiretroviral therapy in the Taipei Veterans General Hospital: a 5-year prospective study.
    Hsu SF; Yang SP; Chan YJ; Wang YW
    J Microbiol Immunol Infect; 2011 Jun; 44(3):198-203. PubMed ID: 21524614
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.
    Ruan Y; Xing H; Wang X; Tang H; Wang Z; Liu H; Su B; Wu J; Li H; Liao L; Li J; Wu JW; Shao Y
    Trop Med Int Health; 2010 Nov; 15(11):1357-63. PubMed ID: 20868414
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
    Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
    Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment.
    Palella FJ; Baker RK; Buchacz K; Chmiel JS; Tedaldi EM; Novak RM; Durham MD; Brooks JT;
    AIDS; 2011 Sep; 25(15):1865-76. PubMed ID: 21811144
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
    Abgrall S; Duval X; Joly V; Descamps D; Matheron S; Costagliola D;
    Clin Infect Dis; 2003 Dec; 37(11):1517-26. PubMed ID: 14614675
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease.
    Imaz A; Falcó V; Peñaranda M; Jordano Q; Martínez X; Nadal C; Curran A; Planes AM; Dalmau D; Ribera E; Riera M; Ruiz de Gopegui E; Pahissa A
    HIV Med; 2009 Jul; 10(6):356-63. PubMed ID: 19490180
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG; Kroon FP; Kauffmann RH; Vriesendorp R; Zwinderman K; van Dissel JT
    Neth J Med; 2003 Dec; 61(12):408-12. PubMed ID: 15025416
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
    Mocroft A; Phillips AN; Friis-Møller N; Colebunders R; Johnson AM; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren JD;
    Antivir Ther; 2002 Mar; 7(1):21-30. PubMed ID: 12008784
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
    Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
    HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.
    Sheng WH; Hsieh SM; Lee SC; Chen MY; Wang JT; Hung CC; Chang SC
    Int J STD AIDS; 2004 Apr; 15(4):249-53. PubMed ID: 15075019
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
    Guillén S; García San Miguel L; Resino S; Bellón JM; González I; Jiménez de Ory S; Muñoz-Fernández MA; Navarro ML; Gurbindo MD; de José MI; Mellado MJ; Martín-Fontelos P; Gonzalez-Tomé MI; Martinez J; Beceiro J; Roa MA; Ramos JT;
    HIV Med; 2010 Apr; 11(4):245-52. PubMed ID: 20050937
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
    Banic S; Koren S; Tomazic J; Vidmar L; Ihan A; Poljak M; Avsic-Zupanc A
    Acta Virol; 2001 Feb; 45(1):39-44. PubMed ID: 11394576
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.
    Piketty C; Weiss L; Thomas F; Mohamed AS; Belec L; Kazatchkine MD
    J Infect Dis; 2001 May; 183(9):1328-35. PubMed ID: 11294663
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
    Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
    Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy.
    Søgaard OS; Schønheyder HC; Bukh AR; Harboe ZB; Rasmussen TA; Ostergaard L; Lohse N
    AIDS; 2010 Jun; 24(9):1315-22. PubMed ID: 20559037
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children.
    Berkelhamer S; Borock E; Elsen C; Englund J; Johnson D
    Clin Infect Dis; 2001 Apr; 32(7):1090-4. PubMed ID: 11264038
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.